Chinese trials in first-line NSCLC and colorectal cancer are imminent.
ApexOnco Front Page
Recent articles
Tacti-004 is terminated for futility, and Immutep crashes 89%.
Ideate-Lung02 goes on global clinical hold.
Astra and Daiichi bag FDA approval based on Destiny-Breast09.
But the Japanese group is focused on biliary tract cancer rather than glioblastoma.
On a cross-trial basis varegacestat beats Ogsiveo.
No fewer than four ADCs with this target start human testing.
Lilly reveals that an Inluriyo/Verzenio combo is being limited to ESR1-mutant disease.
